The estimated Net Worth of Dennis Karl Huang is at least 9.4 百万$ dollars as of 1 March 2023. Mr. Huang owns over 389 units of Ultragenyx Pharmaceutical stock worth over 4,242,438$ and over the last 10 years he sold RARE stock worth over 914,533$. In addition, he makes 4,242,540$ as Chief Technical Operations Officer、 Executive Vice President at Ultragenyx Pharmaceutical.
Dennis has made over 6 trades of the Ultragenyx Pharmaceutical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 389 units of RARE stock worth 17,758$ on 1 March 2023.
The largest trade he's ever made was selling 4,255 units of Ultragenyx Pharmaceutical stock on 1 March 2021 worth over 587,956$. On average, Dennis trades about 316 units every 31 days since 2015. As of 1 March 2023 he still owns at least 75,314 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr. Huang stock trades at the bottom of the page.
Dennis Karl Huang serves as Chief Technical Operations Officer, Executive Vice President of the Company. Prior to Ultragenyx, Mr. Huang served as Senior Vice President of Manufacturing and Supply Chain at InterMune, Inc., a biotechnology company, from August 2013 to March 2015. Prior to InterMune, Mr. Huang served as Vice President of Biologic Manufacturing and Development at Allergan, Inc., a global pharmaceutical company, from May 2006 to August 2013. Mr. Huang currently serves on the board of directors of CytoDel, Inc., a private biopharmaceutical company. Mr. Huang holds a B.A. in Chemistry from Knox College in Galesburg, Illinois.
As the Chief Technical Operations Officer、 Executive Vice President of Ultragenyx Pharmaceutical, the total compensation of Dennis Huang at Ultragenyx Pharmaceutical is 4,242,540$. There are 1 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of 6,586,480$.
Dennis Huang is 55, he's been the Chief Technical Operations Officer、 Executive Vice President of Ultragenyx Pharmaceutical since 2016. There are 16 older and 7 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Dennis's mailing address filed with the SEC is 60 Leveroni Ct, Novato, CA 94949, USA.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over 102,813,606$ worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth 4,623,050$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Llc Fmr、Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of 573,045$. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth 1,117,000$.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: